RMB 329/Shot, Chinese HPV Vaccine to be Available in May

In a major step forward in fighting cervical cancer, a human papillomavirus (HPV) vaccine developed by Chinese researchers will be widely available in the country for women under the age of 45 in May.


The HPV vaccine was jointly developed by Xiamen University and a subsidiary of YangShengTang Group in east China's Fujian Province, after an 18-year study. It was approved by the National Medical Products Administration in December 2019.


Starting next month, the first batch of more than 93,000 vaccines will be available in community hospitals in provincial-level regions including Hubei, Jilin and Xinjiang Uygur Autonomous Region, said a source of the university Sunday.


Cervical cancer is caused by sexually acquired infection with certain types of HPV. It is the third most common cancer among women.


China has a very high incidence and death rate, and previous studies show that for Chinese women the peak incidence of HPV infection occurs between the ages of 15 and 19.


The World Health Organization (WHO) and many countriesrecommend people to get vaccinated between the ages of 9 through 14.


The newly available vaccine can protect against HPV 16 and 18, two major HPV types causing 70 percent of all cervical cancers. It can be given to women aged 9 to 45, according to the source.


British pharmaceutical giant GlaxoSmithKline's Cervarix is the first HPV vaccine introduced in China and the current market-available HPV vaccine with the same type of coverage. Both vaccines require three shots over six months, but the Chinese vaccine is cheaper, with one shot priced at 329 yuan. One shot of Cervarix meanwhile is priced at 580 yuan in the Chinese market.


"Many cervical cancer patients are on low incomes," said Sui Long, a chief gynecologist at the Obstetrics and Gynecology Hospital affiliated to Fudan University in Shanghai, adding that the domestically produced vaccine will make the vaccination affordable for many poor patients.


Due to safety concerns, many vaccines were not available on the Chinese mainland until Cervarix was approved in July 2016. Mainland residents had to travel to Hong Kong or abroad to get the three-shot vaccination, making the cost higher.






Source: xinhua

Editor: Crystal H

Editor's Pick



A Lotus-Shaped Building to Host What?! Strange Monuments List



Summer Vacation Dates Announced for Students in These Cities




Lockdown-Inspired Music Video Goes Viral with Entire Family






\n

Comments